State of Pharma Manufacturing 2019

May 1, 2019

The past year was marked by shifting business models, more stringent quality requirements, technological improvements and mounting political pressures to solve pharma-related policy issues. How has the industry responded?

Spotlight

Dasa

We are leaders in diagnostic medicine in Brazil, the largest company in the sector in Latin America and the 5th largest in the world. We work with clinical analysis, diagnostic imaging and molecular and genomic medicine, with a trajectory of more than 50 years. Each year, we carry out around 250 million tests - an expressive number, comparable to few in the health world.

OTHER WHITEPAPERS
news image

Addressing Viral Pandemics Such as COVID-19 Using the Carterra® LSA

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

Defragmenting Data for the Future of Pharma R&D

whitePaper | November 7, 2019

This in-depth paper will show you how to become data agile – tackling both technological issues and solutions, and the cultural and strategic framework needed around this to ensure success.

Read More
news image

Drug Shortages HSGAC Majority Staff Report 2023

whitePaper | March 1, 2023

Shortages of critical medications continue to rise—including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and even common over-the-counter treatments like children’s cold and flu medicine.

Read More

Spotlight

Dasa

We are leaders in diagnostic medicine in Brazil, the largest company in the sector in Latin America and the 5th largest in the world. We work with clinical analysis, diagnostic imaging and molecular and genomic medicine, with a trajectory of more than 50 years. Each year, we carry out around 250 million tests - an expressive number, comparable to few in the health world.

Events